# A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before

> **NCT04760626** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 1085 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Insulin icodec
- **DRUG:** Insulin Glargine 100U/mL
- **DRUG:** Insulin Degludec
- **DRUG:** Insulin Glargine 300U/mL

## Key facts

- **NCT ID:** NCT04760626
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-01
- **Primary completion:** 2022-08-12
- **Final completion:** 2022-08-29
- **Target enrollment:** 1085 (ACTUAL)
- **Last updated:** 2025-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04760626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04760626, "A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04760626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*